Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Een onderzoek waarin Siplizumab wordt vergeleken met konijn anti-thymocytenglobuline om het lichaam te helpen een niertransplantatie te accepteren (MODERNIZE1)

6 november 2026 bijgewerkt door: ITB-Med LLC

Fase 2b, gerandomiseerde, multicenter, dubbelblinde, dosisvindende, actief-gecontroleerde studie van Siplizumab (TCD601) vergeleken met konijnen anti-thymocyten globuline bij niertransplantatiepatiënten die inductietherapie nodig hebben en standaard immunosuppressie ontvangen met Tacrolimus, mycophenolzuur en corticosteroïden

The goal of this clinical trial is to learn if siplizumab can prevent rejection of a kidney transplant in adult participants with end stage kidney disease. The main questions it aims to answer are:

How many adverse events do participants receiving two different doses of siplizumab have compared to rabbit anti-thymocyte globulin (rATG)?

How many participants successfully keep their kidney transplant after receiving siplizumab or rATG? This will be calculated as those participants that did not: die; have their kidney fail to work properly (graft loss); their body rejects their transplant (tissue sample (biopsy)-proven acute rejection: BPAR); or who were lost to follow-up.

How does the body respond to siplizumab after dosing at each of the 2 dose levels?

How does siplizumab work in the body compared to rATG?

Selected participants will be divided into 3 groups. In 2 of the groups, participants will be given siplizumab at one of the two study medicine doses. Participants in the third group will be given rATG. All participants will take the usual anti-rejection medicines given before, during, and after a kidney transplant. All participants will also be given medicines before the study drug to lower the risk of reactions, and medicines used to prevent or treat infections after the transplant.

Participants will be asked to provide their medical history at the first visit at the study site where you will have your kidney transplant. At the first visit and other visits participants will be asked to provide their medication history, have a physical exam, check vital signs, have blood drawn for tests, and have non-invasive tests that record the electrical activity of your heart (ECG) and blood draws.

Participants will be monitored for 12 months after transplant surgery.

Studie Overzicht

Toestand

Werving

Conditie

Interventie / Behandeling

Gedetailleerde beschrijving

Approximately 120 renal transplant candidates requiring induction therapy will be enrolled 1:1:1 to receive 1 of 2 dose levels of siplizumab or to the comparator rATG.

Randomization will be stratified by donor status (living vs donation after brain death vs donation after cardiac death) to ensure similar proportions of donor types in each study arm. All participants will also receive:

  • A triple regimen (TAC, MPA, and CS) of background immunosuppressive therapy for the duration of the study.
  • Premedication prior to study treatment infusions.
  • Infection prophylaxis

This clinical trial will evaluate the safety of an anti-cluster of differentiation 2 (CD2) monoclonal antibody, siplizumab, compared to rATG as induction therapy in renal transplant recipients.

Following hospital discharge, participants will undergo assessments and procedures as indicated in the protocol through Month 12 or EOS, unless more frequent visits are required per local SoC or for laboratory specimen collection.

Safety assessments will include physical examinations, ECGs, vital signs, viral surveillance and monitoring, standard clinical laboratory evaluations completed centrally (hematology, clinical chemistry, urinalysis), and AE/SAE monitoring.

Final analysis will be performed when all participants have completed 12-month follow-up visits post-transplant or have otherwise ended the trial. This analysis will be performed to evaluate the safety of siplizumab at 2 dose levels compared to rATG.

Studietype

Ingrijpend

Inschrijving (Geschat)

120

Fase

  • Fase 2

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

    • Minas Gerais
      • Belo Horizonte, Minas Gerais, Brazilië, 30150-320
        • Werving
        • Santa Casa Demisericordia de Belo Horizonte
        • Contact:
    • Rio Grande do Sul
      • Porto Alegre, Rio Grande do Sul, Brazilië, 90035-903
        • Werving
        • Hospital de Clinicas de Porto Alegre
        • Contact:
      • Porto Alegre, Rio Grande do Sul, Brazilië, 90020-090
        • Werving
        • Santa Casa de Misericordia de Porto Alegre - Hospital Dom Vincente Scherer
        • Contact:
    • São Paulo
      • São José do Rio Preto, São Paulo, Brazilië, 15090-000
        • Werving
        • Fundação Faculdade Regional de Medicina de São José do Rio Preto - Centro Integrado de Pesquisa
        • Contact:
      • São Paulo, São Paulo, Brazilië, 04038-002
        • Werving
        • Fundação Oswaldo Ramos - Hospital do Rim (HRIM)
        • Contact:
      • Barcelona, Spanje, 08035
        • Werving
        • Hospital Universitari Vall D'Hebron
        • Contact:
      • Córdoba, Spanje, 14004
      • Málaga, Spanje, 29010
        • Werving
        • Hospital Universitario Regional de Malaga
        • Contact:
    • California
      • Los Angeles, California, Verenigde Staten, 90033
        • Werving
        • Keck Hospital of the University of Southern California
        • Contact:
      • Los Angeles, California, Verenigde Staten, 90095
        • Werving
        • University of California - Los Angeles, Connie Frank Kidney Transplant Center
        • Contact:
      • Sacramento, California, Verenigde Staten, 95817
        • Werving
        • UC Davis Medical Center
        • Contact:
    • Florida
      • Tampa, Florida, Verenigde Staten, 33606
        • Werving
        • Tampa General Hospital
        • Contact:
    • Georgia
      • Atlanta, Georgia, Verenigde Staten, 30322
        • Werving
        • Emory University Hospital
        • Contact:
    • Kansas
      • Kansas City, Kansas, Verenigde Staten, 66160
        • Werving
        • University of Kansas Hospital
        • Contact:
    • Kentucky
      • Lexington, Kentucky, Verenigde Staten, 40536
        • Werving
        • University of Kentucky Healthcare
        • Contact:
    • Louisiana
      • Metairie, Louisiana, Verenigde Staten, 70006
        • Werving
        • Tulane Medical Center
        • Contact:
    • Massachusetts
      • Worcester, Massachusetts, Verenigde Staten, 01655
    • Michigan
      • Ann Arbor, Michigan, Verenigde Staten, 48109
        • Werving
        • University of Michigan - Michigan Medicine
        • Contact:
          • Nerissa Reister, Clinical Research Coordinator
          • Telefoonnummer: 734-763-5718
          • E-mail: naflow@med.umich.edu
      • Detroit, Michigan, Verenigde Staten, 48202
        • Werving
        • Henry Ford Health
        • Contact:
    • New Jersey
      • Livingston, New Jersey, Verenigde Staten, 07039
        • Werving
        • Cooperman Barnabus Medical Center
        • Contact:
    • New York
      • New York, New York, Verenigde Staten, 10032
        • Werving
        • New York Presbyterian - Columbia University Irving Medical School
        • Hoofdonderzoeker:
          • Lloyd Ratner, MD
        • Contact:
        • Contact:
      • New York, New York, Verenigde Staten, 10065
        • Werving
        • New York Presbyterian - Weill Cornell Medical Center
        • Contact:
        • Contact:
    • North Carolina
      • Durham, North Carolina, Verenigde Staten, 27710
        • Werving
        • Duke University Medical Center
        • Contact:
    • Texas
      • Dallas, Texas, Verenigde Staten, 75390
    • Virginia
      • Falls Church, Virginia, Verenigde Staten, 22042
        • Werving
        • Inova Fairfax Hospital
        • Contact:
      • Richmond, Virginia, Verenigde Staten, 23298
        • Werving
        • Virginia Commonwealth University Health
        • Contact:
    • Washington
      • Seattle, Washington, Verenigde Staten, 98195
        • Werving
        • University of Washington Medical Center
        • Contact:
          • Belinda Pan, Research Coordinator
          • Telefoonnummer: 206-598-1562
          • E-mail: bcpan@uw.edu

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar tot 70 jaar (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  • Recipients of a renal allograft from a non-HLA identical living or deceased donor.
  • Recipients of a kidney with a cold ischemia time < 30 hours; hypothermic machine perfusion within the same timeframe is acceptable.
  • Women of childbearing potential, defined as all women physiologically capable of becoming pregnant, must agree to use highly effective methods of contraception.

Exclusion Criteria:

  • Transplant recipients seronegative for EBV.
  • Transplant recipients receiving a kidney from a non-heart beating donor (ie, DCD) whose organ is retrieved from an uncontrolled DCD or whose donor age > 55 years of age.
  • Multi-organ transplant recipients (eg, kidney-pancreas, organ other than kidney), dual-kidney transplant recipients, recipients with more than one prior kidney transplant, or hematopoietic stem cell transplantation recipients.
  • Presence of current or historical DSA via single-antigen bead assay or local SoC. The MFI cut-off value used to determine the presence of DSA will be defined as per the institutional SoC. Results within 3 months prior to transplant are acceptable.
  • Crossmatch positive (isolated positive B cell crossmatches are not an exclusion criterion).
  • ABO-incompatible recipient.
  • Administration of complement inhibitor therapy within 6 months prior to the transplant, or likely to require treatment with complement inhibitor therapy during the study.
  • Participants receiving immunosuppressive therapies prior to transplant for pre-existing conditions must be candidates for the protocol-defined regimen.
  • History of malignancy of any organ system, except for localized excised non-melanomatous skin lesions or carcinoma in situ of the cervix.
  • Seropositive for human immunodeficiency virus or hepatitis B surface antigen. Participants who are seropositive for hepatitis C virus (HCV) are excluded without proof of sustained viral response after anti-HCV treatment.
  • Recipient of a kidney from a donor who tests positive for human immunodeficiency virus or hepatitis B surface antigen/hepatitis B core protein.
  • History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes (eg, siplizumab, rATG, TAC, MPA derivatives, CS).
  • Evidence of active tuberculosis (TB) infection (participants with a history of latent TB may become eligible after treatment with anti-TB therapy according to national guidelines).
  • Participants with severe systemic infection(s), at the time of screening or within 2 weeks prior to randomization

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Preventie
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Verviervoudigen

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Lage dosis siplizumab

A non-agonistic, humanized, anti-CD2 monoclonal antibody of the IgG1κ class

Andere namen:
  • TCD601
Experimenteel: Hoge dosis siplizumab

A non-agonistic, humanized, anti-CD2 monoclonal antibody of the IgG1κ class

Andere namen:
  • TCD601
Actieve vergelijker: Konijn anti-thymocyten globuline

An anti-human thymocyte immunoglobulin preparation made of purified polyclonal antibodies derived from rabbits

Andere namen:
  • Thymoglobuline

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Assessment of the safety of 2 dose levels of siplizumab versus rATG.
Tijdsspanne: 12 months

Number and percentage of participants at 12 months post-transplant experiencing adverse events (AEs), serious adverse events (SAEs), and adverse events of special interest (AESIs).

12 months

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Assessment of the incidence of composite efficacy failure (defined as death, graft loss, biopsy-proven acute rejection [BPAR], or loss-to-follow-up) and their individual components.
Tijdsspanne: 12 months
  • Composite incidence of BPAR, death, graft loss, and loss-to-follow-up.
  • Incidence of participants who experienced BPAR as defined by central pathology (blinded independent central review using Banff Allograft Pathology Scoring).
  • Incidence of treated BPAR and steroid-resistant BPAR.
12 months
Assessment of the incidence of composite efficacy failure (defined as death, graft loss, biopsy-proven acute rejection [BPAR], or loss-to-follow-up) and their individual components.
Tijdsspanne: 12 months

• Grade of BPAR.

12 months
Assessment of the incidence of composite efficacy failure (defined as death, graft loss, biopsy-proven acute rejection [BPAR], or loss-to-follow-up) and their individual components.
Tijdsspanne: 12 months

• Severity of BPAR.

12 months
Assessment of the incidence of composite efficacy failure (defined as death, graft loss, biopsy-proven acute rejection [BPAR], or loss-to-follow-up) and their individual components.
Tijdsspanne: 12 months
  • Time to first BPAR for each participant.
  • Time to graft loss for each participant.
  • Time to death for each participant.
12 months
Assessment of the incidence of composite efficacy failure (defined as death, graft loss, biopsy-proven acute rejection [BPAR], or loss-to-follow-up) and their individual components.
Tijdsspanne: 12 months
  • Participant survival at 12 months.
  • Graft survival at 12 months.
12 months
Assessment of the incidence of composite efficacy failure (defined as death, graft loss, biopsy-proven acute rejection [BPAR], or loss-to-follow-up) and their individual components.
Tijdsspanne: 12 months

• Number of participants requiring for-cause renal allograft biopsy assessments over 12 months post-transplant.

12 months
Assessment of the pharmacokinetics (PK) of 2 dose levels of siplizumab.
Tijdsspanne: 12 weeks

Siplizumab Cmax (maximum blood concentration) over 12 weeks post-transplant.

12 weeks
Assessment of the pharmacokinetics (PK) of 2 dose levels of siplizumab.
Tijdsspanne: 12 weeks

Siplizumab AUC (area under the concentration-time curve) over 12 weeks post-transplant.

12 weeks
Assessment of the pharmacodynamics (PD) of 2 dose levels of siplizumab versus rATG.
Tijdsspanne: 12 months

Depletion and recovery of lymphocyte count by subset (total lymphocytes; CD3+, CD4+, and CD8+ T cells; CD19+ B cells; CD56+ NK cells) over 12 months post-transplant.

12 months

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Sponsor

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

29 juni 2026

Primaire voltooiing (Geschat)

28 maart 2028

Studie voltooiing (Geschat)

28 maart 2028

Studieregistratiedata

Eerst ingediend

11 maart 2026

Eerst ingediend dat voldeed aan de QC-criteria

27 maart 2026

Eerst geplaatst (Werkelijk)

2 april 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

12 november 2026

Laatste update ingediend die voldeed aan QC-criteria

6 november 2026

Laatst geverifieerd

1 november 2026

Meer informatie

Termen gerelateerd aan deze studie

Andere studie-ID-nummers

  • TCD601B205

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

NEE

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Ja

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .